Screening for cognitive deficits in 8 to 14-year old children with cerebellar tumors using self-report measures of executive and behavioral functioning and health-related quality of life
Abstract:The PedsQL child- and parent-report and the teacher-report BRIEF and SDQ have moderately good accuracy for discriminating between children with and without a FSIQ < 80. The PedsQL could be used in a clinical setting, and the BRIEF and SDQ in an educational setting, to screen for cases with FSIQ < 80 in children treated for brain tumors.
“…These findings are consistent with other recent studies that have demonstrated some efficacy in using the BRIEF to detect impaired cognitive functioning in survivors of central nervous system tumors. [22, 23] The present study, however, used the BRIEF as the only surveillance measure and related these observations to some documented level of day-to-day deficiency, either in academic achievement or allocation of attentional resources. This study adds to the literature that parents are a reliable fund of information and their report may spot difficulties that affect daily functioning in the home, school, and community settings that might otherwise go undetected.…”
Section: Discussionmentioning
confidence: 99%
“…[20, 21] Recent studies with pediatric brain tumor survivors have shown that the BRIEF identified working memory deficits and was an effective surveillance tool used to identify those with diminished intellectual ability. [22, 23] Brain tumor survivors generally have more severe neurocognitive effects, including both global cognitive and executive functioning, as compared to survivors of other pediatric cancers. [12] It has not been determined whether the BRIEF is a reasonable surveillance measure in pediatric leukemia patients treated without cranial radiation and who generally have meaningful, but less severe, impairment.…”
Neurocognitive problems, including executive dysfunction, are potential late effects of pediatric acute lymphoblastic leukemia (ALL) treatment. Surveillance for neurocognitive impairment in a timely and efficient manner is imperative to ongoing clinical care. We sought to determine if the Behavior Rating Inventory of Executive Function (BRIEF) Parent Form identified leukemia survivors with cognitive impairment. In this 28-site cross-sectional study, parents of 256 children, a mean of 8.9 ± 2.2 years after treatment for standard-risk precursor-B ALL and in first remission, completed the BRIEF. We used a multivariate logistic regression to calculate the association between elevated scores on three composite BRIEF indices (Behavioral Regulation Index (BRI), Metacognition Index (MI), Global Executive Composite (GEC)) and special education and Attention-Deficit/Hyperactivity Disorder (ADHD) outcomes. All BRIEF index scores were significantly associated with receipt of special education services or ADHD. The BRI was most strongly associated with ADHD (OR = 4.33; 95% confidence interval (95% CI) = 1.72 – 10.9). The GEC was most strongly associated with ADHD (OR = 4.46, 95% CI 1.77 – 11.22). Elevated scores on the BRIEF GEC were associated with low sensitivity (24.1 – 39.1) for detecting the outcomes but better specificity (range 87.7 – 89.3). These results suggest that the parent-completed BRIEF is associated with clinical outcomes but is not a sensitive tool to identify leukemia survivors that require a comprehensive neuropsychological assessment.
“…These findings are consistent with other recent studies that have demonstrated some efficacy in using the BRIEF to detect impaired cognitive functioning in survivors of central nervous system tumors. [22, 23] The present study, however, used the BRIEF as the only surveillance measure and related these observations to some documented level of day-to-day deficiency, either in academic achievement or allocation of attentional resources. This study adds to the literature that parents are a reliable fund of information and their report may spot difficulties that affect daily functioning in the home, school, and community settings that might otherwise go undetected.…”
Section: Discussionmentioning
confidence: 99%
“…[20, 21] Recent studies with pediatric brain tumor survivors have shown that the BRIEF identified working memory deficits and was an effective surveillance tool used to identify those with diminished intellectual ability. [22, 23] Brain tumor survivors generally have more severe neurocognitive effects, including both global cognitive and executive functioning, as compared to survivors of other pediatric cancers. [12] It has not been determined whether the BRIEF is a reasonable surveillance measure in pediatric leukemia patients treated without cranial radiation and who generally have meaningful, but less severe, impairment.…”
Neurocognitive problems, including executive dysfunction, are potential late effects of pediatric acute lymphoblastic leukemia (ALL) treatment. Surveillance for neurocognitive impairment in a timely and efficient manner is imperative to ongoing clinical care. We sought to determine if the Behavior Rating Inventory of Executive Function (BRIEF) Parent Form identified leukemia survivors with cognitive impairment. In this 28-site cross-sectional study, parents of 256 children, a mean of 8.9 ± 2.2 years after treatment for standard-risk precursor-B ALL and in first remission, completed the BRIEF. We used a multivariate logistic regression to calculate the association between elevated scores on three composite BRIEF indices (Behavioral Regulation Index (BRI), Metacognition Index (MI), Global Executive Composite (GEC)) and special education and Attention-Deficit/Hyperactivity Disorder (ADHD) outcomes. All BRIEF index scores were significantly associated with receipt of special education services or ADHD. The BRI was most strongly associated with ADHD (OR = 4.33; 95% confidence interval (95% CI) = 1.72 – 10.9). The GEC was most strongly associated with ADHD (OR = 4.46, 95% CI 1.77 – 11.22). Elevated scores on the BRIEF GEC were associated with low sensitivity (24.1 – 39.1) for detecting the outcomes but better specificity (range 87.7 – 89.3). These results suggest that the parent-completed BRIEF is associated with clinical outcomes but is not a sensitive tool to identify leukemia survivors that require a comprehensive neuropsychological assessment.
“…Other studies have reported a significant association between questionnaire scores and direct assessments 48 or proposed the use of QoS questionnaires as screening tools for the presence of neuropsychological deficit 29,49 . However, this was based on observations in a mixed sample of children (malignant and benign brain tumors 48 , brain tumors and healthy controls 29,49,50 ) which may have increased the estimates of sensitivity and specificity of questionnaires compared to that which applies to a population of medulloblastoma survivors.…”
Section: Discussionmentioning
confidence: 99%
“…Other studies have reported a significant association between questionnaire scores and direct assessments 48 or proposed the use of QoS questionnaires as screening tools for the presence of neuropsychological deficit 29,49 . However, this was based on observations in a mixed sample of children (malignant and benign brain tumors 48 , brain tumors and healthy controls 29,49,50 ) which may have increased the estimates of sensitivity and specificity of questionnaires compared to that which applies to a population of medulloblastoma survivors. Several reports have underlined the absence of significant intercorrelations 8,9,21,51 between direct assessments and questionnaire scores and it seems that patients whose direct assessments suggest cognitive compromise do not necessarily present behavioral or cognitive difficulties on questionnaires by self-or proxy-report.…”
Section: Discussionmentioning
confidence: 99%
“…For example, a divergence between direct assessment and questionnaire-based scores of executive function has been consistently observed in patients with traumatic brain injury 25 and cancer [26][27][28] . Previous reports have nevertheless highlighted the usefulness of questionnaire-based assessments in the screening of cognitive deficits in survivors of childhood brain tumors 29 . On the other hand, correlations between scores on different questionnaires assessing various domains of QoS have been moderate or strong.…”
Background: Understanding the global impact of medulloblastoma on health related quality of life (HRQL) is critical to characterizing the broad impact of this disease 448 | and realizing the benefits of modern treatments. We evaluated HRQL in an international cohort of pediatric medulloblastoma patients. Methods: Seventy-six patients were selected from 10 sites across North America, Europe, and Asia, who participated in the Medulloblastoma Advanced Genomics International Consortium (MAGIC). The Health Utilities Index (HUI) was administered to patients and/or parents at each site. Responses were used to determine overall HRQL and attributes (ie specific subdomains). The impact of various demographic and medical variables on HRQL was considered-including molecular subgroup. Results: The majority of patients reported having moderate or severe overall burden of morbidity for both the HUI2 and HUI3 (HUI2 = 60%; HUI3 = 72.1%) when proxy-assessed. Self-care in the HUI2 was rated as higher (ie better outcome) for patients from Western versus Eastern sites, P = .02. Patients with nonmetastatic status had higher values (ie better outcomes) for the HUI3 hearing, HUI3 pain, and HUI2 pain, all P < .05. Patients treated with a gross total resection also had better outcomes for the HUI3 hearing (P = .04). However, those who underwent a gross total resection reported having worse outcomes on the HUI3 vision (P = .02). No differences in HRQL were evident as a function of subgroup. Conclusions: By examining an international sample of survivors, we characterized the worldwide impact of medulloblastoma. This is a critical first step in developing global standards for evaluating long-term outcomes. K E Y W O R D S development, medulloblastoma, pediatric psychology, quality of life, survivors of childhood cancer Abbreviations: ε 2 , epsilon-squared; SD, standard deviation. *Indicates a statistically significant difference (P ≤ .05).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.